Literature DB >> 32008370

Ejaculatory Hood-Sparing Photoselective Vaporization of the Prostate vs Bipolar Button Plasma Vaporization of the Prostate in the Surgical Management of Benign Prostatic Hyperplasia.

Mitali Kini1, Alexis E Te1, James A Kashanian1, Steven Kaplan2, Bilal Chughtai1.   

Abstract

Introduction and
Objectives: After transurethral prostatectomy, erectile dysfunction and ejaculatory dysfunction are significant concerns for patients. We compared ejaculatory hood-sparing technique in patients who underwent photoselective vaporization of the prostate using the GreenLight Laser (EjS-PVP) with the ejaculatory hood-sparing technique in patients who underwent bipolar button plasma vaporization of the prostate (EjS-BPVP) in the surgical management of benign prostatic hyperplasia (BPH). Materials and
Methods: Twenty-seven patients were randomized to either undergo EjS-PVP or EjS-BPVP from August 2016 to March 2018. All of the patients were sexually active with antegrade ejaculation before prostatectomy. We evaluated International Prostate Symptom Score (IPSS), quality of life (QoL), peak flow rate (Qmax), postvoid residual volume (PVR), International Index of Erectile Function and ejaculatory function by the Male Sexual Health Questionnaire (MSHQ). Men were evaluated preoperatively and at 1, 3, and 6 months postoperatively. The primary outcome was ejaculation preservation measured as no change or preservation in antegrade ejaculate at the last follow-up visit by MSHQ (6 months).
Results: Twenty-seven patients with a mean age of 65.6 ± 8.4 years underwent either EjS-BPVP or EjS-PVP (Table 1). There were no differences in baseline characteristics between the two groups. Improvements in IPSS, QoL, Qmax, and PVR were durable throughout the study period in both groups. There was no difference in outcomes between groups. Postoperatively, there was no change in ejaculatory function with EjS-BPVP utilizing either 180 W EjS-PVP or bipolar energy. The change in MSHQ Ejaculation Scale was -2.1 and -5.4 at 6 months in both arms. The 6-month ejaculatory preservation rate was 85% in the EjS-PVP group and 78% in the EjS-BPVP group. Conclusions: EjS GreenLight photoselective vaporization and bipolar plasma button vaporization is a safe and effective method for treating men with lower urinary tract symptoms secondary to BPH with maintenance of antegrade ejaculation.

Entities:  

Keywords:  BPH; GreenLight laser; LUTS; PVP; TURP; TVP; antegrade ejaculation; bipolar TURO; prostate; retrograde ejaculation

Mesh:

Year:  2020        PMID: 32008370     DOI: 10.1089/end.2019.0558

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  4 in total

1.  Ejaculation-sparing versus non-ejaculation-sparing anatomic GreenLight laser enucleo-vaporization of the prostate: first comparative study.

Authors:  Paolo Destefanis; Mattia Sibona; Francesco Soria; Eugenia Vercelli; Federico Vitiello; Andrea Bosio; Alessandro Bisconti; Beatrice Lillaz; Paolo Gontero
Journal:  World J Urol       Date:  2021-02-16       Impact factor: 4.226

2.  Comparison of bipolar plasmakinetic resection of prostate versus photoselective vaporization of prostate by a three year retrospective observational study.

Authors:  Xu Cheng; Chuying Qin; Peng Xu; Yijian Li; Mou Peng; Shuiqing Wu; Da Ren; Lizhi Zhou; Yinhuai Wang
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

3.  Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies.

Authors:  Dean Elterman; Peter Gilling; Claus Roehrborn; Neil Barber; Vincent Misrai; Kevin C Zorn; Naeem Bhojani; Alexis Te; Mitch Humphreys; Steven Kaplan; Mihir Desai; Thorsten Bach
Journal:  BMJ Surg Interv Health Technol       Date:  2021-06-23

Review 4.  Electrosurgery or laser for benign prostatic enlargement: trumpcard or pitfalls.

Authors:  Maximilian Pallauf; Thomas Herrmann; David Oswald; Peter Törzsök; Susanne Deininger; Lukas Lusuardi
Journal:  Curr Opin Urol       Date:  2021-09-01       Impact factor: 2.309

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.